


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61B 6/00	A1	(11) International Publication Number: WO 99/25248 (43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/US98/24033 (22) International Filing Date: 12 November 1998 (12.11.98) (30) Priority Data: 08/972,598 18 November 1997 (18.11.97) US (71) Applicant: CARE WISE MEDICAL PRODUCTS CORPORATION [US/US]; 16390 Monterey Road, Morgan Hill, CA 95037 (US). (72) Inventor: CARROLL, Robert, G.; 11224 Tradewinds Boulevard, Largo, FL 34643 (US). (74) Agent: STEIN, Barry, A.; Caesar, Rivise, Bernstein, Cohen & Pokolitow, Ltd., Seven Penn Center, 12th floor, 1635 Market Street, Philadelphia, PA 19103-2212 (US).		(81) Designated States: CA, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: MINIMALLY INVASIVE SURGICAL PROBE FOR TISSUE IDENTIFICATION AND RETRIEVAL AND METHOD OF USE		

(57) Abstract

The present invention is a probe (20) for detecting, and removing radioactively tagged tissue (12), e.g., a sentinel lymph node, within the body of a living being. The probe is arranged to be inserted through a small percutaneous portal into the patient's body, and is movable to various positions adjacent the tagged tissue (12) to detect the presence of radiation therefrom so that the probe can be positioned immediately adjacent that tissue to ensnare or trap it. The probe can then be removed from the patient's body, carrying the tagged tissue with it. The probe may be constructed to make use of a scintillation crystal (52), a collimator, adjustable or fixed, and a back shielding light pipe (64).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**MINIMALLY INVASIVE SURGICAL PROBE FOR TISSUE
IDENTIFICATION AND RETRIEVAL AND METHOD OF USE**

SPECIFICATION

BACKGROUND OF THE INVENTION

This invention relates generally to medical devices and methods of detection and treatment of cancer, and more particularly to minimally invasive medical systems including a radiation detecting probe for locating radioactively tagged tissue, e.g., a "sentinel" lymph node, within the body of the patient and for retrieving or removing that tissue.

The use of radioactive materials to tag tissue within a patient for effecting its localization and demarcation by radiation detecting devices has been disclosed in the medical literature for at least forty years. Significant developments in the localization and demarcation of tissue bearing radioactive isotope tags for diagnostic and/or therapeutic purposes have occurred since that time. In fact, it is now becoming an established modality in the diagnosis and/or treatment of certain diseases, e.g., cancer, to introduce monoclonal antibodies or other tumor or lymph node localizing agents tagged with a radioactive isotope (e.g., Technetium 99m, Indium 111, Iodine 123, and Iodine 125) into the body of the patient. Such radiopharmaceuticals tend to localize in particular tissue, such as the cancerous tissue, so that the gamma radiation emitted by the isotope agent can be detected by a radiation detector, e.g., a probe. In particular, the radiation detector or probe is disposed or positioned adjacent portion of the patient's body where the cancerous tissue is suspected to be in order to detect if any radiation is emanating from that site. If it is this indicates that cancerous tissue is likely to be found at that site.

Prior art, hand-held, radiation detecting probes particularly suitable for such cancer-finding applications are commercially available from the assignee of this invention, CareWise Medical Products, Inc. under the trademark C-TRAK. In United States Letters Patent Nos. 4,959,547 and 5,036,201 assigned to the same assignee as this invention there are disclosed hand-held radiation detecting probes having collimating means to establish the field of view or "solid angle of acceptance" of the probe. In United States Letters Patent Nos. 5,119,818 and 5,170,055, also assigned to the same assignee as this invention, there are disclosed hand-held radiation detecting probes and accessories optimized to biopsy radio-labeled tissues. In United

States Letters Patent No. 4,801,803 (Donnan et al.) there is also disclosed a hand-held radiation detecting probe.

In the diagnosis and treatment of breast cancer and prostate cancer a radiopharmaceutical can be injected adjacent a detected tumor site, e.g., within the breast, to migrate to the closest draining lymph node (the "sentinel" node) so that localization of that node and its examination can be readily effected in order to evaluate the extent, if any, of metastasis of the cancer. Heretofore, no minimally invasive instrument, e.g., radioactivity detection probe, has existed to not only detect or localize the radioactively tagged tissue, e.g., the sentinel node, but also to engage or otherwise ensnare or trap it so that it can be removed for analysis.

It is a general object of this invention to provide a minimally invasive surgical probe and method of use which overcomes the disadvantages of the prior art.

SUMMARY OF THE INVENTION

These and other objects of the subject invention are achieved by providing a probe for minimally invasive introduction within the body of a living being. The probe is arranged to detect radiation emanating from radioactively tagged tissue, e.g., a sentinel lymph node, within the being's body to determine the location of that tissue. The probe is arranged to be readily manipulated and moved adjacent to the radioactively tagged tissue, and includes means (e.g., plural extendable members) for engaging (e.g., piercing and ensnaring) the radioactively tagged tissue to remove it from the being's body.

DESCRIPTION OF THE DRAWING

Other objects and many attendant features of this invention will become readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawing wherein:

Fig. 1 is an isometric view of a system including the probe assembly of the subject invention;

Fig. 2 is an enlarged longitudinal sectional view of one embodiment of the probe assembly of this invention shown located adjacent radioactively tagged tissue, e.g., a sentinel lymph node, to determine its location so that the probe assembly can be moved to a position wherein a portion of it is located immediately adjacent that tissue;

Fig. 3 is a view, similar to Fig. 2, but showing the probe assembly after it has been moved to a location immediately adjacent the tagged tissue and after its holding means has ensnared, e.g., pierced and trapped, that tissue;

Fig. 4 is an enlarged sectional view taken along line 4 - 4 of Fig. 3;

Fig. 5 is a view similar to Fig. 3, but showing only the distal end of the probe assembly, and wherein the tagged tissue, e.g., lymph node, is too small to be pierced by the holding means, but is nevertheless still snared or entrapped thereby;

Fig. 6 is a longitudinal sectional view of a probe incorporating a single-hole collimator which can be used as part of the probe assembly of the subject invention;

Fig. 7 is a longitudinal sectional view of a probe incorporating a dividable single-hole collimator which can be used as part of the probe assembly of the subject invention;

Fig. 8 is an end view of the divided single-hole collimator shown in its undivided state;

Fig. 9 is an end view of the divided single-hole collimator shown in its divided state; and

Fig. 10 is a longitudinal sectional view of a probe incorporating a back shielding light pipe which can be used as part of the probe assembly of the subject invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring now to the drawing where like reference numerals refer to like parts there is shown at 10 in Figs. 1 a system incorporating a probe assembly 20 constructed in accordance with this invention. The system 10 is preferably constructed and arranged in accordance with the teachings of copending United States Patent Application, Serial No. 08/430,589, filed on April 25, 1995, entitled Apparatus and Methods For Determining Spatial Coordinates of Radiolabelled Tissue Using Gamma Rays And Associated Characteristic X-Rays, which is assigned to the same assignee as this invention and whose disclosure is incorporated by reference herein. The system is arranged to be used with any suitable radiopharmaceutical which is injected or otherwise introduced into the body of the being to be treated for specific uptake by the suspected cancer tissue or sentinel lymph node so that the probe assembly 20 of the system can determine the location of that cancer or lymph node and remove it with minimal invasion to the patient's body. To that end the system 10 basically comprises a minimal access surgical probe assembly 20 and an associated analyzer 22. The probe assembly is coupled to the analyzer by a cable 24 for detecting radiation emanating from the hidden source in a patient, e.g., a sentinel lymph node 12 (Fig. 2) tagged with the radiopharmaceutical, to localize that node, whereupon securement means

(to be described later) in the probe can be operated to engage or otherwise ensnare the node so that it can be removed by the probe from the being's body for analysis.

The probe assembly 20 may be constructed so that it is an integrated instrument, e.g., the radiation detector and associated components and the securement means for ensnaring the node forming a single unit. Alternatively, and as shown in Figs. 2 and 3 the probe assembly 20 may comprise a conventional radiation detecting probe 20A, like that described earlier, and a separate sheath or sleeve 30 for accommodating the probe 20A. To that end the sheath 30 has a central passageway 32 extending through it into which the probe 20A can be located. The sidewall of the sheath includes the heretofore mentioned tissue securement means. The sheath 30 may be constructed so that it is disposable, whereas the radiation detecting probe 20A is reusable. A detachable, side shield 47 in the form of a sleeve of radiation blocking material, may be located on the distal end of the probe assembly for use in high background radiation applications, e.g., when the sentinel node is close to the injection site).

In either case the probe assembly of this invention accomplishes its task by minimal invasive percutaneous penetration into the patient's body at the suspected situs of the lymph node, while the analyzer monitors the radiation picked up by the probe. By monitoring the radiation detected from the radiopharmaceutically-tagged tissue (e.g., gamma radiation, X radiation and/or annihilation radiation) and which is within the probe's solid angle of acceptance 14, the analyzer provides signals to the user to guide him/her so that the probe can be moved (by grasping its proximal end or handle 34) from the position of Fig. 2 to the position of Fig. 3 wherein its distal end 36 is located immediately adjacent the lymph node 12. At this point the tissue securement means (to be described hereafter) can be operated to ensnare the lymph node 12.

In the embodiment shown herein the securement means comprise three extendable, elongated piercing members or wires 38, 40, and 42. Each member is located within a longitudinally extending passageway 44 in the wall of the sheath 30. The members 38, 40, and 42 are arranged to be normally held in a retracted position within the sheath, so that their distal ends 46 are covered as shown in Fig. 3. This enables the probe assembly 20, i.e., the sheath 30 having the probe 20A therein, to be readily inserted either percutaneously or through a surgical incision to an internal situs, e.g., interstitial tissue, in which the distal end 36 of the probe assembly is located adjacent the radioactively tagged tissue 12, without interference caused by

the extending members 38, 40 and 42. The probe can be moved or manipulated while the operator monitors the output of the analyzer 22 in order to locate the distal end of the assembly immediately adjacent the tagged tissue. At this time the extending members 38, 40 and 42 can be operated by means (not shown) to cause their distal ends 46 to extend out, e.g., 5 - 10 mm, of their respective passageways 44.

In accordance with a preferred aspect of this invention the extendable members 38, 40 and 42 are arranged so that, when extended, their distal ends 46 extend inward at an acute angle, e.g., 30 - 60 degrees, to the central longitudinal axis of the probe assembly 20 and intersect each other as shown in Figs. 3 and 4. This action causes the members 38, 40 and 42 to pierce into the tagged tissue, if the tagged tissue is sufficiently large (e.g., 3 - 4 mm or greater in diameter) and thereby "lock" it in place. If the tagged tissue is smaller, the intersecting extendable members 38, 40 and 42 will not pierce the tissue but will otherwise surround it, as shown in Fig. 5. In any case, the probe assembly 20 can then be retracted or withdrawn from the being's body, carrying the tagged tissue 12 with it.

In accordance with one aspect of this invention the sheath may include means to direct the distal ends 46 of the extending members 38, 40 and 42 at an acute angle inward, or those members may be formed so that they automatically assume that orientation when they are extended out of their respective passageways 44 in the sheath 30. Moreover, means (not shown) may be provided to adjust the angle at which the members 38, 40 and 42 extend outward from the sheath.

If additional means are deemed necessary to ensure that the tagged tissue 12 is either trapped between the extending members 38, 40 and 42 and the distal end 36 of the probe assembly 20 (as shown in Fig. 5), or is pierced and ensnared (as shown in Figs. 3 and 4) so that it does not fall off of the probe assembly during the retrieval process, additional holding means (not shown) may be provided. That means may consist of a "purse string" coupled to the extending members 38, 40 and 42 to secure them together and to the ensnared tissue. Moreover, the extending members may include means, e.g., barbs, to ensure that the tissue once grabbed or pierced does not fall off. Such barbs may be annular or longitudinal or combinations of both.

The passageways 44 in the sheath can be used to provide various other functions for the probe assembly. For example suction, from means (not shown), can be used by the probe assembly 20 to aid in holding the tagged tissue 12 in place on the distal end 36 of the probe

assembly 20. The suction means can also be used to remove blood or other fluid from the operative situs.

Energy application means, e.g., a unipolar or bipolar diathermy unit, may be provided to extend out of the sheath 30 in the probe assembly 20. For example, one of the wires 38, 40 or 42 can be a unipolar diathermy wire to be extended into the tagged tissue, if desired. If bipolar diathermy is desired, two of the wires 38, 40 or 42 may be used to provide it.

Any of the passageways 44 in the sheath 30 may be used to deliver any desired material, including biologically active materials, for any desired purpose. For example, any passageway 44 can be used to deliver some flowable material to the situs of the tagged tissue to prevent the migration of cells, e.g., cancer cells, therefrom or to kill such cells.

In order to expedite the tissue localization process the probe assembly may include collimation means, e.g., a snap-on collimator (not shown), an adjustable collimator, (not shown) etc., to establish or adjust the solid angle of acceptance 14 of radioactivity by the probe assembly 20.

While the system 10 may be used without an analyzer 22 constructed in accordance with the teachings of our aforementioned copending patent Application Serial No. 08/430,589, it is preferable to use such an analyzer. In this regard the analyzer can measure the characteristic x-ray photons and full energy gamma ray photons received by the probe's sensor to determine if the ratio of the characteristic x-ray photons to the full energy gamma ray photons is appropriate for the particular radiopharmaceutical used to tag the tissue, i.e., corresponds to the natural abundance of the characteristic x-rays and full energy gamma rays for that radiopharmaceutical. If the ratio is appropriate that fact enables the operator to accurately determine the near field location of the radioactively tagged tumor since there could not be any far field source of radiation which could interfere with the precise location of the tumor (a source of far field radiation would result in an improper ratio of characteristic x-rays to full energy gamma rays). Conversely, an inappropriate ratio, e.g., a reading of significantly more full energy gamma-ray photons than characteristic x-ray photons, will indicate that the source of radiation is far field. Thus, the probe should be moved to a new position, until an appropriate ratio of characteristic x-ray photons to full energy gamma ray photons is detected.

As should be appreciated by those skilled in the art, the "sentinel node" procedure, which is the accepted modality of treatment for melanoma, and which will likely be the accepted

modality of treatment for breast cancer can be effected percutaneously using the subject invention, instead of through conventional cut-down or open surgery, e.g., lumpectomy, as is the case at present. Moreover, the subject invention has particular utility for prostate cancer treatment, wherein the prostate containing the primary tumor is injected with a radiocolloid and any draining lymph nodes exhibiting radioactivity (sentinel lymph nodes) can be removed with minimum invasion to the patient. Similarly, lymph nodes identified by radiolabelled monoclonal antibodies and peptides can be detected and excised with minimum trauma.

The probe assembly 20 of this invention enables one to pierce, and snare or surround, apply suction to, suture or staple selected tagged tissue (e.g., a sentinel lymph node) and thus attach the tagged tissue to the probe tip in order to allow withdrawal of it as the probe is withdrawn. In the embodiment disclosed above the extending members or wires 38, 40 and 42 may be spring steel which are preformed to converge from a straight channel, alternatively they may be straight wires directed by angle channels, or other means in the sheath, or any combination thereof. The extending members may be tubular sections instead of solid wires (for reasons to be discussed later). In any case, the extending members can be adjusted during the operation to vary their angle of attack relative to the energy detecting probe's nose (distal end). A simple adjustment mechanism, such as a purse string attached to the tips of the extending elements can act against the intrinsic springiness or bias of the material making up those elements or can act against the applied force of the portion of the sheath causing the tips to be angled, in order to adjust the angle of attack. The angle can be adjusted from 30 to 60 degrees, in order to pierce and/or entrap and/or apply suction to the smallest lymph nodes. Additionally, at a given angle of attack, the tips of the three extending members can be advanced relative to the probe's tip to better accommodate very large lymph nodes or other tissue chunks. Moreover, at a given angle of attack, the tips of the three extending members can be retracted relative to the probe's tip to better accommodate very small lymph nodes, or other tissue chunks. Additionally, the probe 20A could be retracted relative to the sheath 30, and hence the tips of the extending members or wires 38, 40 and 42, to provide clearance for repositioning the angle of attack and so that they meet closer to the horizontal. As mentioned above, the extending members or wires can include barbs, like "fish hook barbs" and can be from about 0.1 to 3 mm long, designed to spread in response to tissue movement away from the probe's tip.

While the probe is shown with three extending members which are simultaneously advanced into or around the tissue in front of the probe tip the probe can make use of more or less members, as the case may be. In any case the probe can be used under external ultrasound guidance to accurately pierce, snare or surround, apply suction to the selected tagged tissue, while avoiding damage to adjacent blood vessels, nerves, peritoneum, pleura, and other important normal biological structures.

As mentioned earlier, it is also contemplated that the extending members, 38, 40 and 42, instead of being solid wires, can be hollow hypodermic tubing, capable of injecting appropriate substances into the lymph nodes or other tagged tissues to kill tumor cells, or to prevent the spread or seeding of tumor cells, or to initiate and propagate localized blood clotting, or for instilling other local/regional pharmacological agents. Moreover, extending members in the form of hollow tubes enable the application of suction therethrough as an additional attachment mechanism to the lymph node or other tagged tissue. Further still, the suction can be used to remove blood and/or excess fluids. As noted earlier, the channels or passageways 44 in which the extendable wires 38, 40 and 42 are located, can themselves serve as the channels for powerful suction attachment of the lymph node and other tissues. Moreover, these channels or passageways are suitable for injecting any appropriate substance into or around the lymph node or other tissues to kill tumor cells, or to prevent the spread or seeding of tumor cells, or to initiate and propagate localized blood clotting, or for instilling other local/regional pharmacological therapy, or for irrigation and suction of blood and or excess instilled fluids. Moreover, the passageways in which the extending solid wires are located, or the alternative embodiment of tubular wires, or both, can serve as means for installation of fluid solutions for other associated diagnostic and therapeutic purposes.

When the tagged node is ensnared by the probe assembly 20 it can be teased out of surrounding tissue by gentle pressure, under external ultrasound visualization, if desired. Thus, the minimally invasive radiation sensing tissue snaring probe of the invention is particularly suited to locate and retrieve sentinel nodes associated with any solid tumor, such as prostate, breast, lung, colon, rectal, and others. Scarring and trauma is thus minimized. Moreover, trauma-related-release of local growth factors, including platelet derived growth factors, which can lead to tumor reoccurrence, is also minimized.

The probe can be constructed so that it is any desired size. For example, it may be 5 to 16 mm in outside diameter, with a total length of about 9 - 18 inches (228.6 mm - 457.2 mm). Specifically, it may be of an outside diameter of 9.5 mm for easy percutaneous introduction into the suspected site via a conventional 10 mm trocar. The distal end or nose of the probe may be configured to accept a snap on collimator, which may have approximately one millimeter channels bored into the walls, or cast as longitudinal channels or grooves on or within the inner wall of the snap on-collimator. The snap-on collimator may be made of Bismuth alloys or other low-toxicity, low-melting point, easily cast metals, or non-toxic radiation shielding composites, such as Barium filled epoxies.

An additional embodiment may consist of a 5 to 10 mm outside diameter straight probe 20A. An 8 mm version may be ensheathed in a closely fitting disposable plastic, sterile sheath 8.2 mm in inside diameter and 10 mm in outside diameter and including the tissue attachment means, i.e. the extending wires 38, 40 and 42. The optional outer sheathing cylinder 48 (Fig. 2) may be of 10.2 mm inside diameter and 12 mm outside diameter so it can be used to serve as an additional side shielding for the probe assembly 20 during the process of localizing or finding the tagged tissue or node. Alternatively, the sheathing cylinder 48 may be mounted on the probe 20A itself. Moreover, the sheath 48 may be slidable on whatever component it is mounted. The outer sheath 30, i.e., the portion which houses the extending wires 38, 40 and 42, can be made only about 25 mm long and may be constructed of any ionizing radiation shielding material. In use, that sheath may simply be slid back along the longitudinal axis of the probe 20A as the probe penetrates the skin and subcutaneous tissues. That sheath may also simply be slipped off the front of the probe 20A after percutaneous localization of the radioactive node or other tissue, prior to skin penetration. The outer sheath 30 should allow the probe to detect signal from the node as low as 2.5 counts per second, despite noise from the nearby injection site, which may be emitting as much as 37,000 counts per second. Positioning of the leading or distal edge 36 of the outer sheath 30 can be flush with the probe 20A tip or forward of the probe tip, as desired.

The radiation shielding necessary to initially find the node adjacent to a very high background count is substantially greater than the shielding required to track the dissection of that localized node. The sheath 30 or the optional outer sheath 47 may be about 10 half value layers thick (1.9 mm for Tungsten 95% alloy at 140 keV) and the intrinsic probe walls shielding

may be about 7 half value layers thick (1.33 mm for Tungsten 95% alloy at 140 keV). Thus, the reusable probe sheath may be as little as 5 millimeters in diameter (2.66 mm thick with a wall, 2.0 mm diameter radiation detector) while still having 99% exclusion of side incident protons.

The detector may be a rod of Cesium Iodide or of Gadolinium Orthosilicate, either of which is only doped with a scintillation activator at one end to produce an active region approximately 3 mm long, in a rod that may be 100 mm long. In this arrangement, there is no light loss between the scintillation detector portion of the rod and the light pipe, as there would if there were separate joined pieces of scintillator and light pipe. The sides and one end of the rod may be coated with reflective material, such as a thin-layer-deposition of gold, silver, platinum, etc., or a thin-layer-deposition of Teflon reflective material. Thus, a highly efficient, very small diameter intrastitial or endoscopic probe may be constructed, wherein the light pipe material provides backshielding against injection site radioactivity.

The diathermy capability of the probe assembly as described earlier provides the option of cutting attached tissues or of coagulating bleeding vessels. For unipolar or monopolar diathermy coagulation, only one of the extending wires is advanced from the probe tip and the probe is rotated. For bipolar diathermy, two wires are partially advanced, leaving a tissue gap between them. Monopolar diathermy can be accomplished with one or more wires, as desired.

A sterile disposable accessory (not shown) ensheathing the probe can be combined with a sterile disposable probe power cord, or can be combined with a sterile disposable power cord sheath. Alternatively, a self contained probe can be placed inside a "Ziploc" sterile disposable accessory container.

It is also contemplated that the probe itself can be self contained, that is the probe includes radiation signal analyzing circuitry and a self-contained power source, e.g., one or more batteries, for effecting tagged tissue localization and retrieval.

In Fig. 6 there is shown a probe incorporating a single-hole collimator which can be used as part of the probe assembly 20 of the subject invention. That probe is designated by the reference number 20B and basically comprises a cylindrical sidewall 50 formed of a radiation shielding material. A scintillation crystal 52 is located within the interior of the sidewall a short distance proximally of the distal end of the sidewall, so that the sidewall serves as a single hole collimator establishing the probe's solid angle of acceptance 14 for producing a valid signal. A photomultiplier or a photodiode 54 is located distally of the crystal 52 to receive the light flashes

produced by the crystal 52 from radiation impinging on it within the probe's solid angle of acceptance.

Other collimation can be used to reduce or narrow the solid angle of acceptance of the probe of this invention. In fact, such collimation may be adjustable. To that end in Figs. 7 - 9 there is shown a probe incorporating a dividable single-hole collimator which can be used as part of the probe assembly of the subject invention. That probe is designated by the reference number 20C and is identical in construction to probe 20B, except that it includes an operable collimation assembly 56 (to be described hereinafter). In the interests of brevity the common components of probes 20B and 20C will be given the same reference numbers and their construction and operation will not be reiterated. The operable collimation assembly 56 is arranged to be selectively operated in either a "single hole mode," shown in Fig. 9, or in a "divided hole mode," shown in Figs. 7 and 8. In the single hole mode the probe 20C provides a field of view or solid angle of acceptance 14 similar to the probe 20B and which is shown in Fig. 6. In the divided hole mode, the probe 20C provides a narrower solid angle of acceptance 14 like that shown in Fig. 7. To accomplish that end the collimator assembly 56 is made up of plural, e.g., three, hinged pivotable wall members or septa 58. Each of the septa is a planar member made up of a radiation resistant material, e.g., lead, or tungsten or platinum-iridium, and which is hingedly connected at 60 to the inside surface of the cylindrical sleeve 50 immediately distally of the distal end of the scintillation crystal 52 to create two or more channels 62 (in the embodiment shown herein three such channels, to be described hereinafter, are formed as shown in Fig. 8).

When the probe 20C is in the single hole mode the septa 58 are pivoted back to the position shown in Fig. 9, whereupon virtually the entire interior space within the cylindrical sidewall 50 distally of the crystal 52 is available to have radiation pass therethrough within the solid angle of acceptance 14 shown in Fig. 6. In the divided hole mode the septa 58 are pivoted to the operative or closed position shown in Fig. 8 wherein each free edge (i.e., the edge opposite the edge which is pivotally connected to the cylindrical sidewall) engages the respective free edges of the other septa to effectively divide the interior of the cylinder distally of the crystal into three identically sized pie-shaped sectors or channels 62. Each of these channels forms what may be considered its own single hole collimator, so that the combined effect of these three "single hole collimators" is a combined (divided) collimator, whose combined solid angle of acceptance

14 is substantially narrower than when the probe 20C is in the single hole mode as can be seen in Fig. 7.

In Fig. 10 there is shown a probe 20D incorporating radiation back shielding component which can be used as part of the probe assembly of the subject invention. The probe 20D is similar to probe 20B described above, except for the inclusion of a backshielding lightpipe 64 (to be described hereinafter). In the interest of brevity the common features of probes 20B and 20D will be given the same reference numbers. The backshielding lightpipe 64 is formed of any suitable optically transparent but radiation resistant material, e.g., radiopaque, material. As is known, scintillation crystals typically require a dopant to scintillate in response to ionizing radiation. Undoped Gadolinium Orthosilicate or undoped Bismuth Germinate or undoped Cesium Iodide or even a lead-glass lightpipe can be used to form the backshielding lightpipe 64. Thus, with the probe 20D all scintillation events detected by the probe's crystal 52 will be those arising from the front (distal end) of the probe. Ideally the backshielding lightpipe 64 has the same optical index of refraction as the scintillation crystal 52. The simplest way to achieve this goal is to use an undoped light pipe that is made of the same material as the scintillation crystal, with an index of refraction matched optical coupling gel or adhesive (not shown). Alternatively, lead-glass can also be fabricated with various indices of refraction specifications to approximate the index of refraction of the scintillation crystal 52. An optical coupling compound with an index of refraction half way between the crystal and the lightpipe can be used to maximize optical performance of the two part assembly. An alternative, and more elegant approach, is to create a combined scintillator-lightpipe, starting with an undoped crystal lightpipe, that is without the dopant which allows the scintillation crystal to emit flashes of light. In particular, a rod of undoped scintillation crystal, such as undoped Gadolinium Orthosilicate or undoped Bismuth Germinate, or undoped Cesium Iodide is used, but only one end of the rod is doped with the necessary scintillation dopant to form a scintillation crystal at that end, while the undoped portion forms the lightpipe. As will be appreciated, this arrangement will not have an optical joint between the crystal and lightpipe. The deposition of dopants may be accomplished by any implantation technology appropriate to the crystal depth to be treated. Elimination of the optical joint should allow higher spectral resolution and higher sensitivity within the photopeak due to the elimination of optical interface losses.

Without further elaboration the foregoing will so fully illustrate my invention that others may, by applying current or future knowledge, adopt the same for use under various conditions of service.

CLAIMS

What is claimed is:

1. A probe device for minimally invasive introduction within the body of a living being for detecting radiation emanating from radioactively tagged tissue within the being's body to determine the location of the radioactively tagged tissue to enable the probe to be moved adjacent to the radioactively tagged tissue for engaging that tissue and removing it from the being's body.
2. The device of Claim 1 wherein the probe includes at least one extendable member to ensnare the radioactively tagged tissue.
3. The device of Claim 2 wherein said at least one extendable member is arranged to pierce into the radioactively tagged tissue.
4. The device of Claim 3 wherein said probe includes plural extendable member to pierce into the radioactively tagged tissue from plural directions to ensnare it.
5. The device of Claim 1 wherein said probe comprises a body member formed of a radiation blocking material and having radiation detecting means located within said body member, said body member having a distal end portion and a proximal end portion, said proximal end portion being arranged to be held in the hand of a user, said distal end portion being arranged to be directed toward a suspected location of the radioactively tagged tissue.
6. The device of Claim 5 wherein the probe includes at least one extendable member to ensnare the radioactively tagged tissue.
7. The device of Claim 6 wherein said at least one extendable member is arranged to be held in a retracted position with respect to said body of said probe and then extended therefrom to pierce into the radioactively tagged tissue.
8. The device of Claim 6 wherein said probe includes plural extendable members arranged to be held in a retracted position with respect to said body of said probe and then extended therefrom to pierce into the radioactively tagged tissue from plural directions to ensnare it.
9. The device of Claim 5 wherein the radiation detecting means comprises a scintillation crystal.
10. The device of Claim 1 including suction means for holding the radioactively tagged tissue in place with respect to said probe.

11. The device of Claim 1 including suction means for withdrawing blood and/or other fluids.

12. The device of Claim 1 wherein said probe comprises a tubular sheath into which a radiation detector is arranged to be releasably located, said tubular sheath having means to engage the radioactively tagged tissue.

13. The device of Claim 12 wherein said tubular sheath is disposable.

14. The device of Claim 1 comprising collimation means for establishing the solid angle of acceptance of radiation from the radioactively tagged tissue.

15. The device of Claim 14 wherein the collimation means comprises a snap-on collimator.

16. The device of Claim 1 additionally comprising diathermy means for applying energy to the radioactively tagged tissue.

17. The device of Claim 6 wherein said extendable member is barbed.

18. The device of Claim 6 wherein said probe has a longitudinal axis and wherein said extendable member is arranged to be extended at an acute angle to said longitudinal axis.

19. The device of Claim 18 wherein said angle is adjustable.

20. The device of Claim 1 additionally comprising means for introducing a biologically active material adjacent the radioactively tagged tissue.

21. The probe of Claim 1 additionally comprising a collimator for establishing the solid angle of acceptance of the probe.

22. The device of Claim 21 wherein the collimator is adjustable.

23. The device of Claim 22 wherein the adjustable collimator includes at least one movable member arranged to be moved from a first position establishing a first, solid angle of acceptance of the probe, and a second position establishing a second and narrower solid angle of acceptance of the probe.

24. The device of Claim 1 additionally comprising a backshielding member located proximally of said crystal to block radiation from the proximal direction to the crystal.

25. The device of Claim 24 wherein said backshielding member comprises a lightpipe.

26. The device of Claim 25 wherein said lightpipe is formed of a material selected from the group consisting of undoped Gadolineum Orthosilicate, undoped Bismuth Germinate, undoped Cesium Iodide, and lead-glass.

27. The device of Claim 26 wherein said lightpipe is connected to said crystal via an optical interface formed of either an optical coupling gel or adhesive.

28. The device of Claim 26 wherein said crystal and said lightpipe are formed as an integral unit of a material selected from the group consisting of undoped Gadolinium Orthosilicate, undoped Bismuth Germinate, undoped Cesium Iodide, and wherein the crystal is formed of a scintillation doped portion of said material.

29. The device of Claim 9 additionally comprising a collimator for establishing the solid angle of acceptance of the probe.

30. The device of Claim 29 additionally comprising a backshielding member located proximally of said crystal to block radiation from the proximal direction to the crystal.

31. A method of removing radioactively tagged tissue within a living being's body, said method comprising the steps of:

(1) providing a probe for minimally invasive introduction within the body of the being for detecting radiation emanating from radioactively tagged tissue within the being's body,

(2) positioning the probe so that a predetermined portion of the probe is located adjacent the tissue,

(3) operating the probe to snare the tissue,

(4) removing the probe and the snared tissue from the being's body.

32. The method of Claim 31 wherein said radioactively tagged tissue is located within the a cavity, duct, lumen or vessel in the body of the being, and wherein said probe is introduced with minimal invasion of the being's body.

33. The method of Claim 31 wherein said radioactively tagged tissue is located within the an organ in the body of the being, and wherein said probe is introduced with minimal invasion of the being's body.

34. The method of Claim 31 wherein said radioactively tagged tissue is located interstitially, and wherein said probe is introduced with minimal invasion of the being's body.

35. The method of Claim 31 wherein said radioactively tagged tissue comprises a lymph node.

36. The method of Claim 31 additionally comprising the step of providing suction adjacent said radioactively tagged tissue to facilitate the holding of said tissue.

37. The method of Claim 31 additionally comprising the step of providing suction adjacent said radioactively tagged tissue to remove blood and/or other fluids.

38. The method of Claim 31 additionally comprising the step of introducing a flowable material adjacent the radioactively tagged tissue to minimize the migration of cells therefrom.

39. The method of Claim 31 additionally comprising the step of introducing a biologically active material adjacent the radioactively tagged tissue.

40. The method of Claim 31 wherein said probe includes at least one extendable member is arranged to be held in a retracted position with respect to said body of said probe, and wherein said method comprises extending said extendable member from said retracted position to an extended position to snare the tissue.

41. The method of Claim 40 wherein said extendable member is extend to pierce to pierce into the tissue.

42. The method of Claim 41 additionally comprising the step of providing energy to the radioactively tagged tissue.

43. The method of Claim 42 wherein said energy is applied by diathermy means forming a portion of said probe.

44. An instrument for minimally invasive introduction within the body of a living being including a probe and a tissue separator, said probe being arranged for detecting radiation emanating from radioactively tagged tissue within the being's body to determine the location of the radioactively tagged tissue to enable the instrument to be moved adjacent to the radioactively tagged tissue, said tissue separator being arranged to separate the radioactively tagged tissue from adjacent tissue so that the radioactively tagged tissue may be readily removed from the being's body.

45. The instrument of Claim 44 wherein said instrument comprises a grabber for grabbing the radioactively tagged tissue.

46. The instrument of Claim 44 wherein the probe includes at least one extendable member to ensnare the radioactively tagged tissue.

47. The instrument of Claim 46 wherein said at least one extendable member is arranged to pierce into the radioactively tagged tissue.

48. The instrument of Claim 47 wherein said probe includes plural extendable members to pierce into the radioactively tagged tissue from plural directions to ensnare it.

49. The instrument of Claim 48 wherein said plural extendable members are arranged to be extended to a position wherein corresponding portions of each of said extendable member are located immediately adjacent one another.

50. The instrument of Claim 44 wherein said probe comprises a body member formed of a radiation blocking material and having radiation detecting means located within said body member, said body member having a distal end portion and a proximal end portion, said proximal end portion being arranged to be held in the hand of a user, said distal end portion being arranged to be directed toward a suspected location of the radioactively tagged tissue.

51. The instrument of Claim 50 wherein said tissue separator is located at said distal end portion of said body member.

52. The instrument of Claim 50 wherein said instrument comprises a grabber for grabbing the radioactively tagged tissue.

53. The instrument of Claim 50 wherein the probe includes at least one extendable member to ensnare the radioactively tagged tissue.

54. The instrument of Claim 53 wherein said at least one extendable member is arranged to pierce into the radioactively tagged tissue.

55. The instrument of Claim 54 wherein said probe includes plural extendable members to pierce into the radioactively tagged tissue from plural directions to ensnare it.

56. The instrument of Claim 55 wherein said plural extendable members are arranged to be extended to a position wherein corresponding portions of each of said extendable member are located immediately adjacent one another.

57. A method of removing radioactively tagged tissue within a living being's body, said method comprising the steps of:

(1) providing an instrument including a probe and a tissue separator for minimally invasive introduction within the body of the being, said probe being arranged for detecting radiation emanating from radioactively tagged tissue within the being's body and for providing signals indicative thereof,

(2) positioning said probe so that a predetermined portion of said probe is located adjacent the radioactively tagged tissue in response to said signals,

(3) operating said tissue separator to separate the radioactively tagged tissue from adjacent tissue, and

(4) removing the radioactively tagged tissue from the being's body.

58. The method of Claim 57 additionally comprising the step of removing said instrument from the body of the being and removing the radioactively tagged tissue with said instrument.

59. The method of Claim 57 wherein said tissue separator comprises a grabbing member for grabbing the radioactively tagged tissue radioactively tagged tissue and wherein said method comprises operating the grabbing member to grab the radioactively tagged tissue for removing it from the body of the being when said instrument is removed from the body of the being.

60. The method of Claim 59 wherein said grabbing member comprises at least one extendable member, and wherein said method comprises extending said extendable member so that said extendable member pierces the radioactively tagged tissue to grab the radioactively tagged tissue for removing it from the body of the being when said instrument is removed from the body of the being.

61. The method of Claim 60 wherein said grabbing member comprises plural extendable members, and wherein said method comprises extending said extendable members from plural directions so that said extendable members pierce the radioactively tagged tissue to grab the radioactively tagged tissue for removing it from the body of the being when said instrument is removed from the body of the being.

62. The method of Claim 57 wherein said radioactively tagged tissue comprises a tumor.

63. The method of Claim 57 wherein said radioactively tagged tissue comprises a lymph node.

64. The method of Claim 63 wherein said lymph node is a sentinel node.




Fig. 4




Fig. 1




Fig. 2

Fig. 3

Fig. 5




Fig. 8




Fig. 6




Fig. 7




Fig. 9




Fig. 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/24033

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A61B 6/00 US CL : 600/431, 436, 562 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 600/431, 436, 562, 564 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,119,818 A (CARROLL et al) 09 June 1992, entire document.	1-15, 17-19, 21-24, 29-38, 40, 41, 44-64
A	US 4,781,198 A (KANABROCKI) 01 November 1988, Abstract.	1, 31, 44, 57
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* "A" "B" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family
Date of the actual completion of the international search 28 DECEMBER 1998		Date of mailing of the international search report 29 JAN 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer RUTH S. SMITH Telephone No. (703) 308-3063

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.